PMID- 36682712
OWN - NLM
STAT- MEDLINE
DCOM- 20230605
LR  - 20230613
IS  - 1876-4738 (Electronic)
IS  - 0914-5087 (Linking)
VI  - 82
IP  - 1
DP  - 2023 Jul
TI  - Impact of concomitant mitral regurgitation during transcatheter aortic valve 
      replacement on 1-year survival outcomes.
PG  - 16-21
LID - S0914-5087(23)00002-3 [pii]
LID - 10.1016/j.jjcc.2023.01.002 [doi]
AB  - BACKGROUND: We investigated the influence of concomitant mitral regurgitation 
      (MR) in patients undergoing transcatheter aortic valve implantation on the 1-year 
      outcome using Japan Transcatheter Valve Therapy (J-TVT) registry data. METHODS: 
      The patients who underwent the transcatheter aortic valve implantation for aortic 
      stenosis performed from August 2013 to December 2019 in Japan were included. 
      History of previous valve surgery and dialysis patients were excluded. A total of 
      24,979 patients were included, and 1-year follow-up data were obtained from the 
      registry (follow-up rate 98.5 %). Propensity-score matching, using multivariable 
      logistic regression and 1:1 matching without replacement, was performed between 
      the patients with grade 3-4 MR (MR 3-4 group) and those with grade 0-2 MR (MR 0-2 
      group). All-cause death and the composite outcome of death and/or heart failure 
      events were compared. RESULTS: After propensity score matching, 3920 cases (1960 
      cases each in MR 0-2 group and MR 3-4 group) were extracted. The procedure 
      success rate was 96.4 % in MR 0-2 and 96.0 % in MR 3-4 group (p = 0.56) and the 
      surgical conversion rate was 0.7 % in MR 0-2 group and 0.8 % in MR 3-4 group 
      (p = 0.58). Cox regression model showed no statistical difference in 1-year 
      survival rate between MR 0-2 group (89.4 %) and MR 3-4 group (89.6 %) (p = 0.80). 
      However, freedom from 1-year death and/or heart failure event was lower in MR 3-4 
      (86.3 %) than in MR 0-2 group (88.9 %) (p = 0.01). This trend was also found in 
      the subgroup of New York Heart Association (NYHA) class 1-2 but not in the 
      subgroup of NYHA class 3-4. CONCLUSIONS: One-year survival rate was not different 
      between groups but freedom from death and/or heart failure events was lower in 
      patients with preoperative MR grade 3-4 than in patients with preoperative MR 
      grade 0-2 after transcatheter aortic valve replacement.
CI  - Copyright (c) 2023 Elsevier Ltd. All rights reserved.
FAU - Matsuura, Kaoru
AU  - Matsuura K
AD  - Department of Cardiovascular Surgery, Chiba University Graduate School of 
      Medicine, Chiba, Japan. Electronic address: km4717jp@yahoo.co.jp.
FAU - Kumamaru, Hiraku
AU  - Kumamaru H
AD  - Department of Healthcare Quality Assessment, Graduate School of Medicine, The 
      University of Tokyo, Tokyo, Japan.
FAU - Kohsaka, Shun
AU  - Kohsaka S
AD  - Department of Cardiology, Keio University School of Medicine, Tokyo, Japan.
FAU - Kanda, Tomoyoshi
AU  - Kanda T
AD  - Department of Cardiovascular Surgery, Chiba University Graduate School of 
      Medicine, Chiba, Japan.
FAU - Yamashita, Daichi
AU  - Yamashita D
AD  - Department of Cardiology, Chiba University Graduate School of Medicine, Chiba, 
      Japan.
FAU - Kitahara, Hideki
AU  - Kitahara H
AD  - Department of Cardiology, Chiba University Graduate School of Medicine, Chiba, 
      Japan.
FAU - Shimamura, Kazuo
AU  - Shimamura K
AD  - Department of Cardiovascular Surgery, Osaka University Graduate School of 
      Medicine, Suita, Japan.
FAU - Kobayashi, Yoshio
AU  - Kobayashi Y
AD  - Department of Cardiology, Chiba University Graduate School of Medicine, Chiba, 
      Japan.
FAU - Matsumiya, Goro
AU  - Matsumiya G
AD  - Department of Cardiovascular Surgery, Chiba University Graduate School of 
      Medicine, Chiba, Japan.
LA  - eng
PT  - Journal Article
DEP - 20230120
PL  - Netherlands
TA  - J Cardiol
JT  - Journal of cardiology
JID - 8804703
SB  - IM
MH  - Humans
MH  - *Transcatheter Aortic Valve Replacement/methods
MH  - *Mitral Valve Insufficiency/etiology
MH  - Treatment Outcome
MH  - Retrospective Studies
MH  - *Aortic Valve Stenosis
MH  - *Heart Valve Prosthesis Implantation/methods
MH  - *Heart Failure/complications
MH  - Aortic Valve/surgery
MH  - Severity of Illness Index
OTO - NOTNLM
OT  - Aortic valve replacement/implantation
OT  - Outcomes
OT  - Prognosis
OT  - Transcatheter
COIS- Disclosures KM, TK, and GM report the affiliated department received scholarship 
      funds from Otsuka Pharmaceutical. Co., Ltd., Century Medical Inc., Medtronic 
      Japan Co., Ltd., Terumo Corp, Japan lifeline Co., Ltd. KM is a clinical proctor 
      for Edwards Lifesciences. HK reports receiving consultation fees from 
      Mitsubishi-Tanabe Pharma corporation, EPS Corporation, and speaker fees from 
      Chugai Pharmaceutical Co., Ltd., and Johnson and Johnson. KK. SK reports an 
      investigator-initiated grant from Novartis and Daiichi Sankyo and personal fees 
      from Bristol-Myers Squibb. HK and SK are affiliated with the Department of Health 
      Quality Assessment at the University of Tokyo, a social collaboration department 
      supported by the National Clinical Database, Johnson & Johnson K.K., Nipro 
      corporation, and Intuitive Surgical Sarl.
EDAT- 2023/01/23 06:00
MHDA- 2023/06/05 06:42
CRDT- 2023/01/22 19:28
PHST- 2022/10/21 00:00 [received]
PHST- 2022/12/19 00:00 [revised]
PHST- 2022/12/21 00:00 [accepted]
PHST- 2023/06/05 06:42 [medline]
PHST- 2023/01/23 06:00 [pubmed]
PHST- 2023/01/22 19:28 [entrez]
AID - S0914-5087(23)00002-3 [pii]
AID - 10.1016/j.jjcc.2023.01.002 [doi]
PST - ppublish
SO  - J Cardiol. 2023 Jul;82(1):16-21. doi: 10.1016/j.jjcc.2023.01.002. Epub 2023 Jan 
      20.